Sawai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sawai Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sawai Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sawai Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs and OTC drugs. It provides products in the form of tablets, oral dispersing tablets, capsules, granules, injection, tape, ophthalmic and nasal solution and syrup. Sawai Pharmaceutical caters to hospitals, general practitioners, and dispensing pharmacies. The company has manufacturing facilities in Kanto, Kashima, Osaka, Daini, Sanda and Kyusyu. It has its presence in Sapporo, Tokyo Daiichi, Sendai, Kitakanto, Tokyo Daini, Nagoya, Osaka, Hiroshima, and Fukuoka. Sawai Pharmaceutical is headquartered in Osaka, Japan.
Headquarters
Japan
Address
5-2-30, Miyahara, Yodogawa, Osaka, 532-0003
Website
www.global.sawai.co.jp
Telephone
81 6 61055729
No of Employees
2,634
Industry
Pharmaceuticals and Healthcare
Sawai Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cardiovascular Drugs | Xarelto |
| Antihyperlipidemic Agents | Equa |
| OTC Drugs | Onglyza |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In February, the company received approval for six generic drugs with nine strengths from the the Ministry of Health, Labor and Welfare. |
| 2025 | Regulatory Approval | In August, the company received approvals for five generic drugs with 11 strengths, from the the Ministry of Health, Labor and Welfare. |
| 2025 | Contracts/Agreements | In March, the company entered into an agreement with Eisai Co Ltd, under which Eisai will divest its rights for the oral anticoagulant warfarin in Japan to Sawai Pharmaceutical. |
Competitor Comparison
| Key Parameters | Sawai Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | COSMOS Pharmaceutical Corp | Sumitomo Pharma Co Ltd | ASKA Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Yodogawa | Chuo-Ku | Fukuoka-Shi | Osaka | Minato-Ku |
| State/Province | Osaka | Tokyo | Fukuoka | Osaka | Tokyo |
| No. of Employees | 2,634 | 7,778 | 5,709 | 3,832 | 1,632 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Motohiko Kimura | Director; President | Executive Board | - | - |
| Toru Terashima | Director; Group Chief Quality & Safety Officer | Executive Board | 2021 | 65 |
| Seiji Nishimura | Group Chief Marketing Officer | Senior Management | 2021 | - |
| Taku Nakaoka | Chief of Strategic Planning Department | Senior Management | - | - |
| Shoji Yokota | Head - R&D | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer